Torrent Pharmaceuticals Ltd
TORNTPHARMTorrent Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: Foreign institutions moved +3.5 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a confirmed uptrend (168 weeks in) while the P/E sits at the 100th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −26.9% year on year, and 156% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Torrent Pharmaceuticals Ltd trades at ₹4,767, in a confirmed uptrend and 168 weeks into that stage. That is +14.6% against its own 200-day average. It sits at 90% of a 52-week range of ₹3,514 to ₹4,903. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.
Today the stock is in a confirmed uptrend — week 168 of stage 2, confirmed. At ₹4,767 it trades +14.6% versus its 200-day average and sits at 90% of its 52-week range (₹3,514–₹4,903).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +654% while the NIFTY 500 moved +280% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 100th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Torrent Pharmaceuticals Ltd trades at 86.1× P/E, about the priciest it has ever traded. Its long-run median P/E is 41.3×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 86.1× is about the priciest it has ever traded, against a long-run median of 41.3× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +13.2% against a +35.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +26.1%/yr price move, ~+12.0%/yr came from earnings growth and ~+14.1 pp from the multiple (expanding); over 10y, of the +21.0%/yr price move, ~+5.2%/yr came from earnings growth and ~+15.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Torrent Pharmaceuticals Ltd reads as mixed on its fundamental arc. Mixed — the growth curves are steadily positive, but ROCE at 14.1% is below the 15% bar this page requires to call it Consistent. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +21.4% | +13.3% | +11.8% | +7.7% |
| Profit | +11.9% | +19.8% | +11.3% | +2.1% |
| EPS | +13.2% | +20.2% | +11.6% | +2.2% |
| Share price | +35.3% | +34.8% | +26.1% | +21.0% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
38.8/100 — rank 36 of 43 in Pharma - Formulators · 96% evidence confidence
Torrent Pharmaceuticals Ltd scores 38.8 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 36. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 15.4 + 9.8 + 3.8 + 9.8 = 38.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Torrent Pharmaceuticals Ltd reported ₹4,197 Cr of revenue in the Mar 26 quarter, +41.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 7.7% a year. The last full year, FY26, came in at ₹13,980 Cr. The last four reported quarters add to ₹13,980 Cr.
Torrent Pharmaceuticals Ltd reported ₹4,197 Cr of revenue in the Mar 26 quarter, +41.8% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 7.7% a year. The last full year, FY26, came in at ₹13,980 Cr. The last four reported quarters add to ₹13,980 Cr.
FY26 revenue came in at ₹13,980 Cr (+21.4% on the year), capping 10 years at 7.7% compound. The latest quarter (Mar 26) printed ₹4,197 Cr, +41.8% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +21.2% growth against the decade's 7.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +21.4% over the last 4 quarters against +14.2%/yr over the last 8 — accelerating; TTM profit +11.9% vs +13.6%/yr — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 32.0% this quarter (−1.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Torrent Pharmaceuticals Ltd's operating margin is 32.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 22.0% to 41.0%. The current quarter sits inside that band.
Torrent Pharmaceuticals Ltd's operating margin is 32.0% in the Mar 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 22.0% to 41.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 32.0%, −1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 22.0%–41.0%.
🚨 Why the margin moved: operating margin went −0.3 pp year on year while gross margin went +0.5 pp — the loss came mostly from the gross line: input costs and pricing.
→ Margins slipped — did that reach the bottom line? Next: profit −26.9% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Torrent Pharmaceuticals Ltd earned ₹364 Cr of net profit in the Mar 26 quarter, −26.9% year on year. Full-year FY26 profit was ₹2,138 Cr. The 10-year compound rate is 2.1%. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned ₹498 Cr.
Torrent Pharmaceuticals Ltd earned ₹364 Cr of net profit in the Mar 26 quarter, −26.9% year on year. Full-year FY26 profit was ₹2,138 Cr. The 10-year compound rate is 2.1%. That is 8.7% of the quarter's revenue. The same quarter a year earlier earned ₹498 Cr.
Mar 26 profit was ₹364 Cr, −26.9% year on year. On the full year, FY26 printed ₹2,138 Cr (+11.9%), and the 10-year compound rate is 2.1%.
🚨 Why profit moved: revenue contributed +41.8% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +12.4% vs revenue +21.2%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 156% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 156% of Torrent Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹3,023 Cr of operating cash against ₹2,138 Cr of profit. After ₹26,526 Cr of capital spending, ₹−23,503 Cr was left as free cash.
FY26: operating cash of ₹3,023 Cr against reported profit of ₹2,138 Cr, leaving free cash of ₹−23,503 Cr after ₹26,526 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 156% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 156%: the cash cycle tightened 11 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 10.2× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹27,668 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Torrent Pharmaceuticals Ltd's cash conversion cycle runs 163 days in FY26, down from 174 days in FY21. Capital spending ran ₹27,668 Cr over the last 3 years. At FY26 sales of ₹13,980 Cr each day of that cycle holds about ₹38.3 Cr, so roughly ₹6,243 Cr sits inside the business at any moment.
FY26: debtors at 79 days, inventory at 338 days — roughly 11.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 163 days, tighter than FY21's 174.
The full loop: cash goes out to suppliers and production on day 0; stock waits 338 days to sell; customers pay about 79 days after that; and suppliers themselves are paid at 254 days — netting out to the 163-day cycle.
In money terms: at FY26 sales of ₹13,980 Cr, each day of the cycle holds about ₹38.3 Cr — so the 163-day loop keeps roughly ₹6,243 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹27,668 Cr over the last 3 fiscal years against ₹2,722 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹641 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 15% and the ROIC − WACC spread is +0.6 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Torrent Pharmaceuticals Ltd earns a ROCE of 15% in FY26. That is up from a trough of 13% in FY18. Return on invested capital clears the cost of that capital by +0.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 15.3% net margin on 0.32× asset turns.
FY26 ROCE is 15%, recovered from a FY18 trough of 13% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 15.3% net margin × 0.32× asset turns × 5.20× balance-sheet leverage ≈ 25.5% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 12.6% − 12.0% = a +0.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 1.79.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Torrent Pharmaceuticals Ltd carries total debt of ₹15,026 Cr against shareholder equity of ₹17,585 Cr as of Mar 26, a debt-to-equity of 0.85. On the annual view that ratio went from 0.69 in FY22 to 0.85 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹15,026 Cr against shareholder equity of ₹17,585 Cr — a debt-to-equity of 0.85. On the annual view, debt-to-equity went from 0.69 (FY22) to 0.85 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 10.5 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 10.5 points of Torrent Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes promoters to 60.8% of the company. Domestic institutions moved +5.8 points over the same window, to 12.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −10.5 points over 8 quarters to 60.8%; Domestic institutions: +5.8 points over 8 quarters to 12.8%; Foreign institutions: +3.5 points over 8 quarters to 18.0%.
🚨 Why the register moved: promoters drove it (−10.5 points), absorbed on the other side by domestic institutions (+5.8 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Torrent Pharmaceuticals Ltd: the Z-score reads 3.65. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 3.65 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 3.65.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals Ltd this page | 86.1× | ₹1.9L Cr | Consistent | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Torrent Pharmaceuticals Ltd's share price today?
Torrent Pharmaceuticals Ltd trades at ₹4,767, +35.3% over the past year. The company is valued at ₹1,88,720 Cr. The stock sits at 90% of its 52-week range of ₹3,514–₹4,903, +14.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 168 weeks in. — as of 24 July 2026.
What were Torrent Pharmaceuticals Ltd's latest quarterly results?
Torrent Pharmaceuticals Ltd reported revenue of ₹4,197 Cr and net profit of ₹364 Cr for the Mar 26 quarter. Revenue rose 41.8% and profit fell 26.9% year on year. Earnings per share were ₹10.76. The operating margin was 32.0%, 1.0 pp lower than a year earlier. — as of 24 July 2026.
What is Torrent Pharmaceuticals Ltd's revenue?
Torrent Pharmaceuticals Ltd reported revenue of ₹4,197 Cr in the Mar 26 quarter, +41.8% year on year. For the full FY26 fiscal year, revenue was ₹13,980 Cr (+21.4%). Over the last 10 years revenue compounded at 7.7% a year. — as of 24 July 2026.
What is Torrent Pharmaceuticals Ltd's profit?
Torrent Pharmaceuticals Ltd earned ₹364 Cr of net profit in the Mar 26 quarter, −26.9% year on year. Full-year FY26 profit was ₹2,138 Cr. The operating margin ran 32.0% in the latest quarter. — as of 24 July 2026.
What is Torrent Pharmaceuticals Ltd's market cap?
Torrent Pharmaceuticals Ltd's market capitalisation is ₹1,88,720 Cr at a share price of ₹4,767. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Torrent Pharmaceuticals Ltd's P/E ratio?
Torrent Pharmaceuticals Ltd trades at a P/E of 86.1×, at the 100th percentile of its own 10-year range, against a long-run median of 41.3×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Torrent Pharmaceuticals Ltd pay a dividend?
Yes — Torrent Pharmaceuticals Ltd's dividend payout was 59% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Torrent Pharmaceuticals Ltd overvalued?
On its own history, Torrent Pharmaceuticals Ltd looks expensive against its own history: its P/E of 86.1× sits at the 100th percentile of its 10-year range (long-run median 41.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Torrent Pharmaceuticals Ltd growing?
Not right now — Torrent Pharmaceuticals Ltd's latest numbers are shrinking: latest-quarter revenue +41.8% year on year, profit −26.9%, and the margin −1.0 pp at 32.0%. The 10-year compound rates are 7.7% (revenue) and 2.1% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is Torrent Pharmaceuticals Ltd performing?
Torrent Pharmaceuticals Ltd is in a confirmed uptrend, 168 weeks in. Its latest quarter's revenue rose 41.8% and profit fell 26.9% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Torrent Pharmaceuticals Ltd in?
Mixed — the growth curves are steadily positive, but ROCE at 14.1% is below the 15% bar this page requires to call it Consistent. The read comes from the last 12 quarters of growth (revenue growth +21.4% latest, profit growth +11.9% latest, eps growth +11.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Torrent Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 168 of stage 2), trading +14.6% versus its 200-day average and at 90% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Torrent Pharmaceuticals Ltd beating the market?
On recent form, yes — Torrent Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +654% against the NIFTY 500's +280% — ahead of the index over the full window. — as of 24 July 2026.
Will Torrent Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Torrent Pharmaceuticals Ltd. What it measures instead: the share price is ₹4,767, the price is in a confirmed uptrend 168 weeks in. Its P/E of 86.1× sits at the 100th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Torrent Pharmaceuticals Ltd?
Promoters hold 60.8% of Torrent Pharmaceuticals Ltd, foreign institutions 18.0%, domestic institutions 12.8% and the public 8.4% (latest quarter). The biggest move on the register over the last two years: Promoters cut 10.5 points over 8 quarters. — as of 24 July 2026.
Does Torrent Pharmaceuticals Ltd have too much debt?
It carries real leverage — Torrent Pharmaceuticals Ltd's debt-to-equity is 1.79, and operating profit covers the interest bill 12×. FY26 borrowings were ₹15,026 Cr against equity of ₹8,388 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Torrent Pharmaceuticals Ltd's capex?
Torrent Pharmaceuticals Ltd spent ₹27,668 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹26,526 Cr, with ₹641 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Torrent Pharmaceuticals Ltd's cash flow?
Torrent Pharmaceuticals Ltd generated ₹3,023 Cr of operating cash flow in FY26 and ₹−23,503 Cr of free cash flow after ₹26,526 Cr of capital spending. Reported profit that year was ₹2,138 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Torrent Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 156% of Torrent Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹3,023 Cr against reported profit of ₹2,138 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Torrent Pharmaceuticals Ltd?
On the balance sheet, the Z-score reads 3.65 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Torrent Pharmaceuticals Ltd in its business cycle?
Torrent Pharmaceuticals Ltd's FY26 operating margin was 33.0%, against a 13-year band of 22.0%–41.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 32.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Torrent Pharmaceuticals Ltd story?
The sharpest disagreement: Foreign institutions moved +3.5 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Torrent Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Torrent Pharmaceuticals Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.